Regeneron Says Trevogrumab Preserves Muscle During GLP-1-Induced Weight Loss

MT newswire2026/10/01 16:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

12:39 PM EDT, 10/01/2026 (MT Newswires) -- Regeneron Pharmaceuticals (REGN) reported new results from a phase 2 trial that evaluated trevogrumab for its potential to prevent muscle and lean mass loss during weight loss from GLP-1 drugs. In a predefined MRI analysis, trevogrumab prevented 70% of the muscle loss associated with semaglutide, the company said Thursday in a statement. Patients with low lean mass, a marker of sarcopenia, lost more lean mass on semaglutide and showed greater preservation with trevogrumab. Based on the results, Regeneron plans to start a phase 2 trial combining trevogrumab with GLP-1 therapies in older adults with obesity and low muscle mass or strength. Price: 727.86, Change: -30.41, Percent Change: -4.01

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hulamin said independent non-executive director Paul Baloyi resigned, effective Oct. 2, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hulamin Ltd. published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S604350), on October 05, 2026, and is solely responsible for the information contained therein.

Bitget•2026/10/05 14:30

US Stock Move | Pneumococcal vaccine achieves late-stage clinical trial target, Vaxcyte (PCVX.US) opens more than 50% higher

On Monday, Vaxcyte (PCVX.US) soared more than 50% at the open and was up approximately 53% at the time of writing, with a market capitalization of 12.8 billions USD.

智通财经•2026/10/05 13:47